<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский онкологический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-9984</issn><issn publication-format="electronic">2412-9119</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">40390</article-id><article-id pub-id-type="doi">10.18821/1028-9984-2017-22-5-274-276</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">THE EFFECTIVENESS OF COMBINED TREATMENT OF DISSEMINATED MALIGNANT PLEURAL MESOTHELIOMA, A DESCRIPTION OF THE CLINICAL CASE</article-title><trans-title-group xml:lang="ru"><trans-title>ЭФФЕКТИВНОСТЬ КОМБИНИРОВАННОГО ЛЕЧЕНИЯ ДИССЕМИНИРОВАННОЙ ЗЛОКАЧЕСТВЕННОЙ МЕЗОТЕЛИОМЫ ПЛЕВРЫ, ОПИСАНИЕ КЛИНИЧЕСКОГО СЛУЧАЯ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Karpenko</surname><given-names>Tat’yana D.</given-names></name><name xml:lang="ru"><surname>Карпенко</surname><given-names>Татьяна Дмитриевна</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, Postgraduate of the Department of Chemotherapy of the Research Institute of Clinical Oncology, Moscow, 115478, Russian Federation</p></bio><bio xml:lang="ru"><p>аспирант отделения химиотерапии НИИ клинической онкологии</p></bio><email>katan4ik@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bychkov</surname><given-names>M. B</given-names></name><name xml:lang="ru"><surname>Бычков</surname><given-names>М. Б</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-10-15" publication-format="electronic"><day>15</day><month>10</month><year>2017</year></pub-date><volume>22</volume><issue>5</issue><issue-title xml:lang="en">VOL 22, NO5 (2017)</issue-title><issue-title xml:lang="ru">ТОМ 22, №5 (2017)</issue-title><fpage>274</fpage><lpage>276</lpage><history><date date-type="received" iso-8601-date="2020-07-22"><day>22</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, ООО "Эко-Вектор"</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">ООО "Эко-Вектор"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://rjonco.com/1028-9984/article/view/40390">https://rjonco.com/1028-9984/article/view/40390</self-uri><abstract xml:lang="en"><p>Modern approach to the individualization of the management of patients based on the careful observation for the minimal manifestations of the disease, prescription of pemetrexed at the first line of therapy, combination with platinum preparations and antiangiogenic targeted preparation bevazisumab allows control the disease at the advanced stage of pleural mezoteliom and support the good active state of patients during the long time.</p></abstract><trans-abstract xml:lang="ru"><p>Современный подход к индивидуализации лечения больных, основанный на тщательном наблюдении за минимальными проявлениями болезни, назначении пеметрекседа в первой линии лечения, комбинации с препаратами платины и антиангиогенным таргетным препаратом бевацизумабом, позволяет контролировать заболевание в распространённой стадии мезотелиомы плевры и поддерживать хорошее активное состояние пациентов в течение длительного времени.</p></trans-abstract><kwd-group xml:lang="en"><kwd>pleural mesothelioma</kwd><kwd>chemotherapy</kwd><kwd>individualization of treatment</kwd><kwd>stabilization of disease</kwd><kwd>combined treatment</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>мезотелиома плевры</kwd><kwd>химиотерапия</kwd><kwd>индивидуализация лечения</kwd><kwd>стабилизация болезни</kwd><kwd>комбинированное лечение</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Бычков М.Б., Большакова С.А., Бычков Ю.М. Мезотелиома плевры: современная тактика лечения. Современная онкология. 2005; 7(3): 142-4.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Бычков М.Б., Карпенко Т.Д. Мезотелиома плевры (диагностика, лечение). Сибирский онкологический журнал. 2013; 2: 17-8.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Яблонский П.К., Петров А.С. Злокачественная мезотелиома плевры. Практическая онкология. 2006; 3: 179-86.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003; 21(14): 2636-44.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Ceresoli G.L., Zucali P.A., Favaretto A.G. et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J. Clin. Oncol. 2006; 24: 1443-38.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Zalcman G., Mazieres J., Margery J. et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016; 387: 1405-14.</mixed-citation></ref></ref-list></back></article>
